MiniMed Group (MMED) Stock Overview
Operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MMED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MiniMed Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.47 |
| 52 Week High | US$24.43 |
| 52 Week Low | US$10.65 |
| Beta | 0 |
| 1 Month Change | 8.55% |
| 3 Month Change | 48.22% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 21.53% |
Recent News & Updates
Closed Loop Diabetes Ecosystem Will Unlock High Margin Recurring Revenue Potential
Catalysts About MiniMed Group MiniMed Group develops integrated diabetes management systems that combine insulin delivery, continuous glucose monitoring and software into a connected ecosystem. What are the underlying business or industry changes driving this perspective?MiniMed Group: Recurring Revenues And Fresh Product Cycle
Summary MiniMed’s pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED’s Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off. MMED’s valuation is also relatively cheap. So, given that there’s an upcoming product cycle, I believe the stock is very compelling for long-term investors today. Read the full article on Seeking AlphaRecent updates
Closed Loop Diabetes Ecosystem Will Unlock High Margin Recurring Revenue Potential
Catalysts About MiniMed Group MiniMed Group develops integrated diabetes management systems that combine insulin delivery, continuous glucose monitoring and software into a connected ecosystem. What are the underlying business or industry changes driving this perspective?MiniMed Group: Recurring Revenues And Fresh Product Cycle
Summary MiniMed’s pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED’s Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off. MMED’s valuation is also relatively cheap. So, given that there’s an upcoming product cycle, I believe the stock is very compelling for long-term investors today. Read the full article on Seeking AlphaShareholder Returns
| MMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.5% | -5.8% | -2.2% |
| 1Y | n/a | -19.9% | 13.1% |
Return vs Industry: Insufficient data to determine how MMED performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how MMED performed against the US Market.
Price Volatility
| MMED volatility | |
|---|---|
| MMED Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MMED's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 8,000 | Que Dallara | www.minimed.com |
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D.
MiniMed Group, Inc. Fundamentals Summary
| MMED fundamental statistics | |
|---|---|
| Market cap | US$6.31b |
| Earnings (TTM) | -US$314.00m |
| Revenue (TTM) | US$3.22b |
Is MMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMED income statement (TTM) | |
|---|---|
| Revenue | US$3.22b |
| Cost of Revenue | US$1.39b |
| Gross Profit | US$1.83b |
| Other Expenses | US$2.15b |
| Earnings | -US$314.00m |
Last Reported Earnings
Jul 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 56.89% |
| Net Profit Margin | -9.75% |
| Debt/Equity Ratio | 0% |
How did MMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 23:44 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/07/31 |
| Annual Earnings | 2026/04/24 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiniMed Group, Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Travis Steed | BofA Global Research |
| Marie Thibault | BTIG |